{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:58:18Z","timestamp":1769752698863,"version":"3.49.0"},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T00:00:00Z","timestamp":1543363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Relapsed cHL patients after autologous hematopoietic stem cell transplantation (HSCT) with treatment\u2010sensitive disease are potential candidates for curative allogeneic HSCT. However, there are some concerns around performing such procedure after checkpoint inhibitors (CPIs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We collected published data of patients undergoing allogeneic HSCT after treatment with CPIs (cohort 1). Abstracts of recent conferences (2015\u20102017; ASCO, ASH, EBMT, ASBMT) were also included. Results were compared with safety of recent studies (2015\u20102018) with allogeneic HSCT without CPIs (cohort 2).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 272 records were screened. After exclusion of duplications, cohorts 1 and 2 included each 6 publications with 122 and 978 patients, respectively. Grade 3\u20104 acute GVHD in cohort 1 was found in 28% vs 8% in cohort 2 (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.02). Chronic GVHD was observed in 26% vs 29%, respectively. NRM was 15% which remained relatively stable after 6\u00a0months of allogeneic HSCT vs 19% in cohort 2.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This is the largest pooled analysis of its kind published so far. Our results suggest that allogeneic HSCT after CPIs is feasible and not associated with higher mortality. However, careful consideration should be given for prevention, early detection, and effective treatment of GVHD in these cases. Additional prospective studies are needed for further clarification.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13186","type":"journal-article","created":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T17:04:07Z","timestamp":1540055047000},"page":"150-156","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Allogeneic hematopoietic stem cell transplantation in r\/r Hodgkin lymphoma after treatment with checkpoint inhibitors: Feasibility and safety"],"prefix":"10.1111","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8221-9342","authenticated-orcid":false,"given":"Reyad","family":"Dada","sequence":"first","affiliation":[{"name":"King Faisal Specialist Hospital and Research Centre  Jeddah Saudi Arabia"},{"name":"College of Medicine Al\u2010Faisal University Riyadh Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binyam","family":"Usman","sequence":"additional","affiliation":[{"name":"King Faisal Specialist Hospital and Research Centre  Jeddah Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,11,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3226-0"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.158"},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","unstructured":"Carlo\u2010StellaCC ArmandG ZinzaniP et al.Allogeneic hematopoietic stem cell transplantation outcomes after nivolumab monotherapy for relapsed\/refractory Hodgkin lymphoma (CheckMate 039 and CheckMate 205). The European Society for Blood and Marrow Transplantation; March 27 2017; Marseille France2017;Oral presentation","DOI":"10.1016\/j.clml.2017.07.136"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-738385"},{"key":"e_1_2_8_6_1","first-page":"45712016","article-title":"Checkpoint inhibitor therapy and graft versus host disease in allogeneic bone marrow transplant recipients of haploidentical and matched products with post\u2010transplant cyclophosphamide","volume":"128","author":"Laura K","year":"2016","journal-title":"Blood"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx341"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.69"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.44"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.03.028"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23897"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.11.030"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6869"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-016-2134-3"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.194"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.02.022"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.332"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4557"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-302109"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.6545"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.107"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2016.12.019"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71017-4"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.3.1272"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/85330"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13186","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13186","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13186","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T09:23:30Z","timestamp":1694251410000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,28]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1111\/ejh.13186"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13186","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,28]]},"assertion":[{"value":"2018-09-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}